Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and veliparib

lapatinib has been researched along with veliparib in 3 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(veliparib)		Trials
(veliparib)		Recent Studies (post-2010) (veliparib)
1,9193051,44232587286

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)veliparib (IC50)
Poly [ADP-ribose] polymerase 1Homo sapiens (human)0.0469
Protein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)1.9027
Poly [ADP-ribose] polymerase 2Homo sapiens (human)0.0688
Protein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)3.4837
Protein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)2.089

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Cooper, T; Nowsheen, S; Stanley, JA; Yang, ES1
Acosta, EP; Caterinicchia, V; Chen, D; Della Manna, DL; Falkson, CI; Forero-Torres, A; Li, Y; May, JE; Nabell, LM; Olariu, E; Rocque, GB; Stringer-Reasor, EM; Vaklavas, C; Yang, ES1

Trials

1 trial(s) available for lapatinib and veliparib

ArticleYear
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    Breast cancer research : BCR, 2021, 03-04, Volume: 23, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease Management; Drug Monitoring; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms

2021

Other Studies

2 other study(ies) available for lapatinib and veliparib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Breaks, Double-Stranded; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Transport; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinational DNA Repair; Tumor Burden; Xenograft Model Antitumor Assays

2012